Key highlights
- Achieved 100% responder rate across all nine treated patients to date
- High-dose cohort demonstrated greater improvements in throat emptying at the 3-month mark
- Low-dose cohort (Cohort 1) showed continued durable improvements through 12 months post-treatment
- 100% of high-dose patients met statistical criteria for improved throat emptying vs 67% in low-dose
- Pivotal study design confirmation with the FDA is targeted for the first quarter of 2027
Phase 1b/2a Clinical Data Analysis
Benitec Biopharma reported interim clinical results from its ongoing Phase 1b/2a first-in-human study of BB-301, an investigational gene therapy for patients suffering from OPMD-related dysphagia. The study evaluated two dose cohorts, with the high-dose group (Cohort 2) showing 100% responder rates for improved throat emptying ability as assessed by videofluoroscopic evaluation. This compares to a 67% responder rate in the low-dose group at the same three-month post-treatment time-point. Additionally, the high-dose cohort exhibited greater functional swallowing capacity improvements in the Cold-Water Timed Drinking Test, signaling a positive dose-response relationship essential for future trial design.
Therapeutic Significance for OPMD
- Confirms the effectiveness of the 'Silence and Replace' platform in treating rare genetic muscular disorders
- Provides clinical validation for the transition to a pivotal study planned for mid-2027
- Demonstrates 12-month durability in the low-dose cohort, suggesting long-term efficacy
- High-dose results highlight potential for superior clinical outcomes in swallowing functionality
- Addresses a critical unmet medical need for OPMD patients who currently have no approved therapies
Company Background and Pipeline
Headquartered in Hayward, California, Benitec Biopharma is a clinical-stage biotechnology company leveraging its proprietary DNA-directed RNA interference platform. The technology seeks to provide a singular therapeutic intervention by silencing disease-causing genes while simultaneously replacing them with functional copies. BB-301 is the company's flagship asset, designed specifically for OPMD, a condition characterized by progressive muscle weakness and life-threatening swallowing complications. The recent data reinforces the potential of this dual-action mechanism to establish a new standard of care in the field of genetic medicine.
Financial and Strategic Position
As a pre-commercial biotechnology entity, Benitec Biopharma maintains a focused capital allocation strategy toward the development of BB-301. The company possesses a market capitalization of approximately $302.8 million and reported a cash position of approximately $180.0 million as of June 30, 2026. Management has indicated that these reserves are sufficient to fund clinical operations for at least 12 months, covering the lead-up to the pivotal trial. The company’s financial stability was previously bolstered by a $100.0 million capital raise in late 2025, providing the necessary runway to reach critical regulatory milestones in early 2027.
Down 1.6% since our story on 28 Oct: $8.68 when we broke it → $8.54 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $8.36 |
|---|---|
| 20 Oct | $9.04 |
| 21 Oct | $8.50 |
| 22 Oct | $8.82 |
| 23 Oct | $8.65 |
| 26 Oct | $8.59 |
| 27 Oct | $8.68 |
| 28 Oct | $8.80 |
| 29 Oct | $8.83 |
| 30 Oct | $8.74 |
| 2 Nov | $8.49 |
| 3 Nov | $8.40 |
| 4 Nov | $9.28 |
| 5 Nov | $8.64 |
| 6 Nov | $9.54 |
| 9 Nov | $9.87 |
| 10 Nov | $9.28 |
| 11 Nov | $9.47 |
| 12 Nov | $9.09 |
| 13 Nov | $9.04 |
| 16 Nov | $8.54 |
CEO Perspectives on Clinical Progress
“Progressive loss of swallowing function has a devastating impact on OPMD Patients, yet there are no approved therapies to address this critical unmet medical need. The progress we continue to see regarding both the safety and efficacy of BB-301 reinforces our conviction in the program and the potential to establish a new treatment paradigm for Patients suffering from OPMD-related dysphagia.”
| Date | Announcement | Amount |
|---|---|---|
| 05 Oct 2026 | Regulatory update following Type C meeting with FDA for BB-301 pivotal studySource: benitec.com | – |
| 14 Sep 2026 | Full year 2026 financial results and operational updateSource: otcmarkets.com | – |
| 14 May 2026 | Third quarter 2026 financial results and operational updateSource: benitec.com | – |
| 28 Apr 2026 | Interim Phase 1b/2a clinical study results for BB-301 presented at ASGCT Annual MeetingSource: stocktitan.net | – |
| 12 Feb 2026 | Second quarter 2026 financial results and operational updateSource: benitec.com | – |
| 06 Nov 2025 | Pricing of underwritten public and registered direct common stock offeringsSource: benitec.com | $100.0 Million |
Management commentary
“Progressive loss of swallowing function has a devastating impact on OPMD Patients, yet there are no approved therapies to address this critical unmet medical need.”
| Share price | $8.68 |
|---|---|
| Market cap | $303M |
| 1-month price change | -9.49% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Benitec Biopharma Inc. announcing positive interim Phase 1b/2a results for its BB-301 gene therapy candidate.
Track Benitec Biopharma Inc. live
Get the next Benitec Biopharma Inc. SEC filing seconds after it lands.